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Amelioration of intestinal and systemic 
sequelae of murine Campylobacter jejuni 
infection by probiotic VSL#3 treatment
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Abstract 
Background: The incidence of human Campylobacter jejuni infections is progressively increasing worldwide. Pro-
biotic compounds might open up valuable tools to decrease pathogen burden and subsequent pro-inflammatory 
immune responses, but in vivo data are scarce.
Methods and results: Secondary abiotic mice generated by broad-spectrum antibiotic treatment were perorally 
challenged with the commercial probiotic compound VSL#3 consisting of Streptococcus thermophilus, Bifidobacterium 
breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacil-
lus paracasei, and Lactobacillus delbrueckii ssp. bulgaricus) either 5 days before (i.e. prophylactic regimen) or after (i.e. 
therapeutic regimen) peroral C. jejuni strain 81–176 infection, and analyzed 3 weeks following the initial bacterial re-
association. Upon challenge, mice were colonized with the probiotic bacteria and/or C. jejuni at comparable intestinal 
loads, but co-colonization did not result in reduction of the pathogen burden. Remarkably, prophylactic as well as 
therapeutic VSL#3 treatment of C. jejuni infected mice ameliorated intestinal apoptosis and pro-inflammatory immune 
responses as indicated by lower numbers of innate and adaptive immune cell populations in the murine colon upon 
probiotic prophylaxis or treatment and reduced colonic concentrations of pro-inflammatory mediators including 
IL-6 and MCP-1. Importantly, concentrations of anti-inflammatory mediators such as IL-10 were significantly elevated 
in the colon of probiotics treated mice as compared to untreated controls. Strikingly, prophylactic VSL#3 treatment 
attenuated C. jejuni induced systemic pro-inflammatory responses as indicated by less TNF and IL-12p70 secretion in 
the spleen of VSL#3 pre-treated as compared to non-treated mice.
Conclusion: Administration of probiotic formulations such as VSL#3 might open up valuable strategies for prophy-
laxis and/or treatment of C. jejuni induced intestinal and systemic sequelae in vivo by the suppression of pro-inflam-
matory and induction of anti-inflammatory responses.
Keywords: Probiotic compound, VSL#3, Secondary abiotic mice, Gnotobiotic mice, Bacterial in vivo competition, 
Pathogen–commensal bacteria–host interaction, Apoptosis, Innate and adaptive immune cells, Pro-inflammatory 
cytokines, Anti-inflammatory cytokines, Extra-intestinal and systemic sequelae of infection
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Background
The enteric bacterial pathogen Campylobacter jejuni 
is regarded as a commensal within the intestinal tract 
of wild and domestic animals, but highly virulent in 
humans acquiring the pathogen usually by consump-
tion of contaminated products derived from livestock 
animals or contaminated surface water via the peroral 
route [1–3]. Whereas Campylobacter infections are on 
the rise worldwide [4–6], patients present with gastroen-
teritis of varying degree ranging from mild malaise and 
watery diarrhea to severe ulcerative colitis with inflam-
matory, bloody diarrhea [7]. In the vast majority of 
cases, intestinal disease resolves spontaneously, whereas 
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systemic post-infectious sequelae including peripheral 
neuropathies such as Guillain-Barré-syndrome, Miller-
Fisher syndrome or reactive arthritis might develop with 
a latency of weeks to months [8–10]. Due to the lack of 
suitable experimental in  vivo models of campylobacte-
riosis, our understanding of the molecular mechanisms 
underlying Campylobacter-host interactions has been 
hampered for a long time [3, 11]. Conventionally colo-
nized mice, for instance, are protected from C. jejuni 
infection due to the host specific microbiota composi-
tion exerting physiological colonization resistance [3, 12]. 
Previous results from our own experiments revealed that 
modification of the murine intestinal microbiota facili-
tated C. jejuni infection [12, 13]. Upon virtual eradication 
of the intestinal microbiota by broad-spectrum antibi-
otic treatment secondary abiotic mice became highly 
susceptible to C. jejuni colonization and exhibited key 
features of human campylobacteriosis such as apoptosis 
and inflammation in the colon [12]. Notably, colonization 
resistance was restored in secondary abiotic mice recolo-
nized with a murine microbiota. Thus, both secondary 
abiotic mice and secondary abiotic animals re-colonized 
with a murine microbiota are well suited to unravel the 
triangular relationship between intestinal pathogens, 
bacteria and the host immune system in vivo [12, 14].
Given the importance of the distinct intestinal micro-
biota composition in rendering the vertebrate host resist-
ant against enteric pathogens including C. jejuni, interest 
in the potential of “beneficial” modulations of the micro-
biota composition in humans as well as in livestock ani-
mals has arisen. One promising strategy is the application 
of probiotics, defined as live microorganisms which, 
when administered in adequate concentrations, bestow 
health benefits to the host [15]. There are numerous indi-
cations from both in  vitro and in  vivo studies pointing 
out the efficacy of probiotics in therapy and prevention 
of enteric infections. Strains of probiotic microorgan-
isms such as Lactobacillus acidophilus, Lactobacillus 
casei, Lactobacillus rhamnosus, Lactobacillus gasseri, and 
Bifidobacterium lactis, for instance, have been shown to 
inhibit growth, metabolism and adhesion of enteropatho-
genic bacteria including C. jejuni, Salmonella, Shigella, 
enterotoxigenic Escherichia coli or Vibrio cholerae to 
intestinal cells [16–20]. Furthermore, effects of probiot-
ics have been examined in clinical studies for a number 
of gastrointestinal diseases. For instance, randomized 
trials suggest that co-administration of VSL#3, a pro-
biotic compound consisting of eight different bacterial 
strains [21], or Saccharomyces boulardii [22] significantly 
decrease the incidence of antibiotics associated diarrhea 
(AAD). Moreover, episodes of infectious diarrhea in both 
adults and children can be shortened by the use of probi-
otics [23]. A meta-analysis of 74 experimental studies, 84 
clinical trials and more than 10,000 patients revealed that 
probiotics were effective in the therapy and prevention of 
several gastrointestinal diseases including AAD, Clostrid-
ium difficile toxin induced acute enterocolitis (the most 
severe form of AAD), infectious diarrhea, pouchitis and 
irritable bowel syndrome, but not of travelers’ diarrhea 
or necrotizing enterocolitis [24]. However, the underly-
ing mechanisms of the probiotic effect are yet not fully 
understood. Proposed mechanisms of action include, for 
instance, modification of the intestinal microbiota [25], 
enhancement of colonization resistance [26] and intesti-
nal barrier functions [27], as well as modulation of innate 
and adaptive immune functions [28].
In the present study, we examined the beneficial effects 
exerted by prophylactic and therapeutic treatment of C. 
jejuni infected mice with the probiotic compound VSL#3. 
We addressed, whether peroral VSL#3 application would 
lower intestinal pathogenic burden in the host, down-
regulate C. jejuni induced pro-inflammatory seque-
lae and/or conversely, up-regulate anti-inflammatory 
immune responses not only locally (i.e. in the intestinal 
tract), but also in extra-intestinal compartments includ-
ing systemic compartments.
Methods
Generation of secondary abiotic mice
Female C57BL/6j mice were bred and maintained 
within the same specific pathogen free (SPF) unit in the 
Forschungseinrichtungen für Experimentelle Medizin 
(FEM, Charité-University Medicine Berlin). Second-
ary abiotic mice virtually lacking an intestinal micro-
biota were generated by broad-spectrum antibiotic 
treatment for 8  weeks as described previously [29]. 
In brief, 8–10  week old mice were transferred to ster-
ile cages and treated with a quintuple broad-spectrum 
antibiotic cocktail consisting of ampicillin plus sulbac-
tam (1  g/L; Ratiopharm, Ulm, Germany), vancomycin 
(500  mg/L; Cell Pharm, Hannover, Germany), cipro-
floxacin (200  mg/L; Bayer Vital, Leverkusen, Germany), 
imipenem (250  mg/L; MSD, Haar, Germany) and met-
ronidazole (1  g/L; Fresenius, Bad Homburg, Germany) 
via the drinking water ad  libitum for 8  weeks. Absence 
of cultivable bacteria in feces samples (applying thiogly-
colate enrichment broths; Oxoid, Wesel, Germany) for 
at least three consecutive weeks was used as a quality 
control for the successful depletion of the gut microbiota 
[29].
Probiotic treatment and C. jejuni infection of secondary 
abiotic mice
Three days prior to bacterial re-colonization or infec-
tion experiments the quintuple antibiotic cocktail was 
withdrawn and replaced by autoclaved tap water. Mice 
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were perorally infected with  109 colony forming units 
(CFU) C. jejuni strain 81–176 in 0.3 mL sterile phosphate 
buffered saline (PBS) by gavage as described earlier [12]. 
For probiotic re-colonization, mice received a suspen-
sion of the commercial formulation VSL#3 (probiotic 
food supplement; Manufacturer: SIIT S.r.l, Trezzano sul 
Naviglio, Italy; distributed by Actial Farmaceutica, Fun-
chal, Madeira, Portugal) consisting of the following eight 
bacterial species: Streptococcus thermophilus, Bifidobac-
terium breve, Bifidobacterium longum, Bifidobacterium 
infantis, Lactobacillus acidophilus, Lactobacillus plan-
tarum, Lactobacillus paracasei, and Lactobacillus del-
brueckii ssp. bulgaricus). A total of 4.5 ×  1011 probiotic 
bacteria were dissolved in 50 mL sterile PBS. By gavaging 
0.3 mL (either five days before or after C. jejuni infection), 
each mouse received  109 viable probiotic bacteria as 
confirmed by cultural analyses of the suspensions. Mice 
infected either with the pathogen or re-colonized with 
the probiotic formulation alone as well as naive unin-
fected mice served as controls. Mice were continuously 
kept in a sterile environment (autoclaved food and drink-
ing water) and were handled under strict aseptic condi-
tions to prevent from contaminations.
Sampling procedures
Tissue samples from colon, mesenteric lymph nodes 
(MLN) and spleen were removed under sterile condi-
tions. Colonic ex vivo biopsies were collected in parallel 
for microbiological and immunological analyses. Immu-
nohistopathological changes were determined in colonic 
samples that had been immediately fixed in 5% formalin 
and embedded in paraffin. Sections (5 μm) were stained 
with respective antibodies for in situ immunohistochem-
istry as described earlier [30].
Quantitative analysis of C. jejuni or probiotic bacterial 
colonization
Viable C. jejuni strain 81–176 were detected in feces or 
at time of necropsy in luminal samples taken from the 
colon, dissolved in sterile PBS and serial dilutions cul-
tured on Karmali- and Columbia-Agar supplemented 
with 5% sheep blood (Oxoid, Wesel, Germany) for two 
days at 37  °C under microaerobic conditions using 
CampyGen gas packs (Oxoid) as described earlier [12]. 
Probiotic bacteria of the formulation VSL#3 were quan-
titated in serial dilutions streaked onto Columbia-Agar 
supplemented with 5% sheep blood and Columbia-CNA 
Agar supplemented with colistin and nalidixic acid (both 
Oxoid) in parallel and incubated under aerobic (with 5% 
 CO2), microaerophilic (in jars using CampGen gas packs; 
Oxoid) and obligate anaerobic (in jars using Anaerogen 
gas packs; Oxoid) conditions for at least 2  days. Bacte-
rial species were identified according to their typical 
morphological appearances and confirmed by 16S rRNA 
based sequencing. The total probiotic bacterial loads in 
intestinal samples were assessed by the sum of identified 
CFU derived from the respective culture conditions. The 
detection limit of viable bacteria was ≈100 CFU per g.
Immunohistochemical stainings of colonic ex vivo biopsies
In situ immunohistochemical analysis of colonic paraf-
fin sections was performed as described previously [12, 
31, 32]. Primary antibodies against cleaved caspase-3 
(Asp175, Cell Signaling, USA, 1:200), Ki67 (TEC3, Dako, 
Glostrup, Denmark, 1:100), CD3 (#N1580, Dako, Den-
mark, dilution 1:10), FOXP3 (FJK-16s, eBioscience, San 
Diego, CA, USA, 1:100), B220 (eBioscience, 1:200) and 
F4/80 (# 14-4801, clone BM8, eBioscience, 1:50) were 
used. The average numbers of positively stained cells 
within at least six high power fields (HPF, 400× magnifi-
cation) were determined for each animal microscopically 
by an independent blinded investigator.
Cytokine detection in culture supernatants of ex vivo 
biopsies taken from colon, mesenteric lymph nodes 
and spleen
Colonic ex  vivo biopsies were cut longitudinally and 
washed in PBS. MLN, spleen or strips of approximately 
1  cm2 colonic tissue were placed in 24-flat-bottom well 
culture plates (Nunc, Wiesbaden, Germany) containing 
500 μL serum-free RPMI 1640 medium (Gibco, life tech-
nologies, Paisley, UK) supplemented with penicillin (100 
U/mL) and streptomycin (100 µg/mL; PAA Laboratories, 
Pasching, Austria). After 18  h at 37  °C, culture super-
natants were tested for TNF, MCP-1, IL-6, IL-12p70, 
and IL-10 by the Mouse Inflammation Cytometric Bead 
Assay (CBA; BD Biosciences, Heidelberg, Germany) on a 
BD FACSCanto II flow cytometer (BD Biosciences).
Statistical analysis
Medians and levels of significance were determined 
using Mann–Whitney test (GraphPad Prism v5, La Jolla, 
CA, USA) as indicated. Two-sided probability (p) val-
ues ≤0.05 were considered significant.
Results
Intestinal colonization densities in secondary abiotic mice 
following peroral re‑colonization with probiotic bacteria 
and/or C. jejuni strain 81–176 infection
In the present study we investigated the potential of pro-
biotic bacteria in the commercial formulation VSL#3 to 
reduce pathogen burdens and to ameliorate pro-inflam-
matory immune responses upon C. jejuni infection 
in vivo. To address this, secondary abiotic mice were gen-
erated by broad-spectrum antibiotic treatment of con-
ventionally reared mice. These mice were virtually lacking 
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intestinal bacteria and hence, physiological colonization 
resistance was abrogated to assure stable intestinal pro-
biotic bacterial colonization and/or C. jejuni infection 
[11, 12]. Secondary abiotic mice were then perorally chal-
lenged with a probiotic suspension (i.e. VSL#3) contain-
ing  109 viable bacteria in total by gavage either 5  days 
before (i.e. prophylactic regimen) or after (i.e. therapeutic 
regimen) peroral C. jejuni strain 81–176 infection (with 
 109 CFU) and compared to control mice that were either 
challenged by probiotic bacteria or C. jejuni alone. Unin-
fected, naive mice served as negative controls. In fact, 
probiotic bacteria as well as C. jejuni could stably colo-
nize the murine intestinal tract, both with high median 
loads of approximately  109 CFU per gram feces, irrespec-
tive of the re-colonization regimen (n.s.; Fig.  1). Nei-
ther in the therapeutic nor prophylactic re-colonization 
group, however, probiotic bacteria were able to lower C. 
jejuni burden as indicated by comparably high pathogen 
loads in fecal samples over time, and the same was true 
the other way around (n.s.; Fig. 1c, d). If compared to C. 
jejuni mono-infected mice, however, fecal pathogen loads 
were approximately 0.25 orders of magnitude lower in 
mice of the probiotic treatment group at day 21 following 
C. jejuni infection (p < 0.005; Fig. 2).
Overall, mice could be stably re-associated with pro-
biotic bacteria and/or C. jejuni, but co-colonization did 
not result in a biologically relevant reduction of either 
bacteria.
Macroscopic and intestinal sequelae of C. jejuni infection 
and probiotic treatment
Given that re-association with probiotic bacteria and/or 
C. jejuni strain 81–176 infection did not macroscopically 
(i.e. clinically) compromise secondary abiotic mice (not 
shown), we next investigated potential intestinal sequelae 
resulting from respective bacterial challenges. Given that 
apoptosis is a well-established marker for histopathologi-
cal grading of intestinal inflammation and a key feature 
Fig. 1 Kinetic of intestinal probiotic bacterial and/or C. jejuni strain 81–176 loads in perorally associated secondary abiotic mice. Secondary abiotic 
mice were generated by broad-spectrum antibiotic treatment and perorally re-associated with a the probiotic compound VSL#3 (white symbols) 
on day (d) 0, b C. jejuni strain 81–176 (Cj; black symbols) on d0, c VSL#3 on day 0 and C. jejuni strain 81–176 on d5 or d C. jejuni strain 81–176 (d0) and 
VSL#3 on d0 as described in “Methods”. Bacterial colonization densities were assessed in fecal samples (CFU/g, colony forming units per gram) over 
time upon re-association as indicated by culture. Medians (black bars) and levels of significance (p value) determined by Mann–Whitney U test are 
indicated. Numbers of analyzed mice are given in parentheses. Data were pooled from three independent experiments. N.d. not determined
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of campylobacteriosis [12], we quantitatively assessed 
large intestinal epithelial caspase3  +  cell numbers by 
in situ immunohistochemistry. Numbers of colonic apop-
totic cells were higher in C. jejuni infected mice of either 
group as compared to naive or VSL#3 mono-associated 
mice (p < 0.05–0.001; Fig. 3a). These increases, however, 
were far less pronounced in VSL#3 co-colonized mice of 
either regimen as indicated by approximately 50% lower 
apoptotic cell numbers as compared to C. jejuni infected 
mice (p < 0.005–0.001; Fig. 3a). Notably, re-association of 
mice with the probiotic compound alone was not asso-
ciated with colonic apoptosis (Fig.  3a). Given that Ki67 
comprises a nuclear factor necessary for cellular pro-
liferation [33], we additionally stained colonic paraffin 
sections with Ki67 antibodies to assess potential pro-
liferative (and thus regenerative) measures of the large 
intestinal epithelium counteracting apoptosis. Bacterial 
or pathogenic mono- as well as co-association resulted 
in increases of Ki67+  colonic epithelial cell numbers 
(p < 0.001; Fig. 3b) with a trend towards highest numbers 
in mice that were co-colonized with probiotic bacteria 
and C. jejuni (n.s. vs C. jejuni alone; p < 0.05–0.005 ver-
sus VSL#3 alone; Fig. 3b). Hence, prophylactic as well as 
therapeutic challenge of C. jejuni infected mice with the 
probiotic compound VSL#3 resulted in less pronounced 
large intestinal apoptotic responses.
Intestinal and systemic pro‑ and anti‑inflammatory 
responses upon probiotic treatment of C. jejuni infected 
mice
Since recruitment of pro-inflammatory immune cells to 
the site of infection is a key feature of intestinal inflam-
mation in the course of campylobacteriosis [12], we next 
quantitatively assessed distinct innate as well as adaptive 
immune cell subsets in large intestinal ex  vivo biopsies, 
again applying in  situ immunohistochemistry. Peroral 
C. jejuni infection, but not VSL#3 re-colonization alone 
was associated with increases in colonic numbers of T 
and B lymphocytes, regulatory T cells (Treg) as well as 
macrophages and monocytes (p  <  0.001; Fig.  4). These 
increases, however, were significantly less pronounced in 
with probiotics treated C. jejuni infected mice, irrespec-
tive whether VSL#3 was applied prophylactically or ther-
apeutically (p < 0.05–0.001; Fig. 4).
We further measured pro- and anti-inflammatory 
cytokine concentrations in large intestinal ex  vivo biop-
sies. Bacterial mono- as well as co-association were 
accompanied by increases in colonic pro-inflammatory 
Fig. 2 Fecal bacterial loads in C. jejuni strain 81–176 infected and/or VSL#3 associated secondary abiotic mice. Secondary abiotic mice were 
generated by broad-spectrum antibiotic treatment and perorally re-associated with the probiotic compound VSL#3 (white symbols) on day (d) 0, C. 
jejuni strain 81-176 (Cj; black symbols) on day 0, VSL#3 (day 0) and C. jejuni strain 81–176 (day 5) or C. jejuni strain 81–176 (day 0) and VSL#3 (day 5) as 
described in “Methods”. Bacterial colonization densities were assessed in fecal samples (CFU/g, colony forming units per gram) at day 21 upon initial 
re-association as indicated by culture. Medians (black bars) and level of significance (p value) determined by Mann–Whitney U test are indicated. 
Numbers of analyzed mice are given in parentheses. Data were pooled from three independent experiments. N.d. not determined
Page 6 of 13Ekmekciu et al. Gut Pathog  (2017) 9:17 
mediators including TNF, MCP-1, and IL-6 (p  <  0.05–
0.001; Fig.  5a–c). C. jejuni induced increases in colonic 
MCP-1 and IL-6, but not increased TNF concentrations 
could be dampened by prophylactic probiotic treat-
ment (p  <  0.05; Fig.  5a–c). Notably, IL-6 levels were 
also decreased in large intestines derived from C. jejuni 
infected mice of the therapeutic VSL#3 cohort (p < 0.05; 
Fig. 5c) and did not differ from IL-6 concentrations meas-
ured in naive controls (n.s.; Fig. 5c). Notably, large intes-
tinal concentrations of the anti-inflammatory cytokine 
IL-10 were increased upon mono- and co-association with 
the probiotic compound as compared to naive controls 
(p < 0.05–0.001; Fig. 5d). Moreover, VSL#3 application of 
either regimen resulted in elevated IL-10 concentrations 
in C. jejuni infected mice (p < 0.05; Fig. 5d).
We next measured cytokine levels in another intestinal 
compartment. In MLN, concentrations of respective pro- 
and anti-inflammatory cytokines increased upon bacte-
rial and/or pathogenic re-association (p  <  0.05–0.001; 
Fig.  6). Prophylactic probiotic treatment of C. jejuni 
infected mice, however, resulted in slightly lower IL-10 
concentrations when compared to C. jejuni mono-associ-
ated mice (p < 0.05; Fig. 6d).
We further assessed systemic cytokine responses upon 
bacterial and/or pathogenic challenges of secondary abi-
otic mice. C. jejuni induced increases in splenic TNF 
concentrations could be slightly lowered following pro-
biotic pre-treatment (p < 0.05; Fig. 7a), but not if probi-
otic treatment followed C. jejuni infection. In addition, 
mice of the prophylactic cohort exhibited lower IL-12p70 
concentrations in their spleen as compared to C. jejuni 
infected animals (p  <  0.05; Fig.  7b), whereas C. jejuni 
infection was associated with increased splenic IL-6 
secretion (p < 0.05–0.005; Fig. 7c) that could neither be 
lowered by prophylactic nor therapeutic probiotic chal-
lenges. Notably, splenic IL-10 concentrations were unaf-
fected upon bacterial re-colonization and/or pathogenic 
infection (n.s.; Fig. 7d).
Taken together, less colonic apoptosis upon probiotic 
co-administration in C. jejuni infected mice was accom-
panied by lower numbers of innate and adaptive immune 
cell populations in the large intestinal mucosa and 
lamina propria and less secretion of pro-inflammatory 
mediators, whereas anti-inflammatory IL-10 concen-
trations were increased in the colon upon prophylac-
tic or therapeutic VSL#3 treatment of C. jejuni infected 
Fig. 3 Apoptotic and proliferating cells in the colonic epithelium of C. jejuni strain 81–176 and/or VSL#3 associated secondary abiotic mice. Second-
ary abiotic mice were perorally associated either with the probiotic compound VSL#3 (+VSL; white symbols) or with C. jejuni strain 81–176 (+Cj; 
black symbols) on day 0. In bacterial competition experiments VSL#3 associated mice were challenged with C. jejuni strain 81–176 5 days thereaf-
ter (+VSL + Cj) or, the other way around (+Cj + VSL), C. jejuni infected mice additionally associated with the probiotic compound. The average 
numbers of colonic a apoptotic cells (positive for caspase-3, Casp3) and b proliferating cells (positive for Ki67) from six high power fields (HPF, 400× 
magnification) per animal were determined microscopically in immunohistochemically stained colonic paraffin sections at day 21 upon initial 
bacterial association. Naive mice served as uninfected controls (black diamonds). Medians (black bars), numbers of analyzed animals (in parenthe-
ses) and levels of significance (p values) determined by Mann–Whitney U test are given. Significant differences as compared to naive controls are 
indicated by asterisks (**p < 0.01; ***p < 0.001). Data were pooled from four independent experiments
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Fig. 4 Colonic immune cell responses in C. jejuni strain 81–176 and/or VSL#3 associated secondary abiotic mice. Secondary abiotic mice were pero-
rally associated either with the probiotic compound VSL#3 (+VSL; white symbols) or with C. jejuni strain 81-176 (+Cj; black symbols) on day 0. In bac-
terial competition experiments VSL#3 associated mice were challenged with C. jejuni strain 81–176 5 days thereafter (+VSL + Cj) or, the other way 
around (+Cj + VSL), C. jejuni infected mice additionally associated with the probiotic compound. The average numbers of colonic a T lymphocytes 
(positive for CD3), b regulatory T cells (Treg; positive for FOXP3), c B lymphocytes (positive for B220), and d macrophages and monocytes (positive 
for F4/80) from six high power fields (HPF, 400× magnification) per animal were determined microscopically in immunohistochemically stained 
colonic paraffin sections at day 21 upon initial bacterial association. Naive mice served as uninfected controls (black diamonds). Medians (black bars), 
numbers of analyzed animals (in parentheses) and levels of significance (p-values) determined by Mann–Whitney U test are given. Significant differ-
ences as compared to naive controls are indicated by asterisks (***p < 0.001). Data were pooled from four independent experiments
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mice. Furthermore, prophylactic VSL#3 challenge could 
dampen C. jejuni induced TNF responses in the systemic 
(i.e. splenic) compartment.
Discussion
Although C. jejuni are the most commonly reported 
bacterial etiological agents of diarrhea in developed 
Fig. 5 Colonic secretion of pro- and anti-inflammatory cytokines in C. jejuni strain 81-176 and/or VSL#3 associated secondary abiotic mice. 
Secondary abiotic mice were perorally associated either with the probiotic compound VSL#3 (+VSL; white symbols) or with C. jejuni strain 81–176 
(+Cj; black symbols) on day 0. In bacterial competition experiments VSL#3 associated mice were challenged with C. jejuni strain 81–176 5 days 
thereafter (+VSL + Cj) or, the other way around (+Cj + VSL), C. jejuni infected mice additionally associated with the probiotic compound. a TNF, b 
MCP-1, c IL-6 and d IL-10 concentrations were determined in colonic ex vivo biopsies at day 21 upon initial bacterial association. Naive mice served 
as uninfected controls (black diamonds). Medians (black bars), numbers of analyzed animals (in parentheses) and levels of significance (p-values) 
determined by Mann–Whitney U test are given. Significant differences as compared to naive controls are indicated by asterisks (*p < 0.05; **p < 0.01; 
***p < 0.001). Data were pooled from four independent experiments
Page 9 of 13Ekmekciu et al. Gut Pathog  (2017) 9:17 
countries [3], in  vivo data regarding the molecular 
mechanisms underlying pathogen-host interactions are 
still scarce, partly due to lack of suitable mouse mod-
els mimicking C. jejuni induced immunopathology in 
humans. We have previously shown that intestinal micro-
bial depletion following antibiotic treatment of mice can 
overcome physiological colonization resistance against 
C. jejuni that is elicited by the murine host specific 
microbiota composition [12]. Apart from that, C. jejuni 
infected secondary abiotic mice exhibit immunopatho-
logical key features of human campylobacteriosis, thus 
providing a well-suited model to further unravel interac-
tions between enteropathogens and the vertebrate host 
[3, 11, 12]. Given the importance of the distinct micro-
biota composition in disease susceptibility and progres-
sion, secondary modulation of the intestinal microbiota 
by application of probiotic compounds has arisen as an 
attractive preventive or therapeutic approach. In bacterial 
Fig. 6 Secretion of pro- and anti-inflammatory cytokines in mesenteric lymph nodes derived from C. jejuni strain 81–176 and/or VSL#3 associated 
secondary abiotic mice. Secondary abiotic mice were perorally associated either with the probiotic compound VSL#3 (+VSL; white symbols) or with 
C. jejuni strain 81–176 (+Cj; black symbols) on day 0. In bacterial competition experiments VSL#3 associated mice were challenged with C. jejuni 
strain 81–176 5 days thereafter (+VSL + Cj) or, the other way around (+Cj + VSL), C. jejuni infected mice additionally associated with the probiotic 
compound. a TNF, b MCP-1, c IL-6 and d IL-10 concentrations were determined in ex vivo biopsies derived from mesenteric lymph nodes (MLN) 
at day 21 upon initial bacterial association. Naive mice served as uninfected controls (black diamonds). Medians (black bars), numbers of analyzed 
animals (in parentheses) and levels of significance (p-values) determined by Mann–Whitney U test are given. Significant differences as compared to 
naive controls are indicated by asterisks (*p < 0.05; **p < 0.01; ***p < 0.001). Data were pooled from three independent experiments
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in vivo competition experiments applying our secondary 
abiotic mouse model, we here investigated changes in 
intestinal pathogen burden and host immune responses 
upon peroral C. jejuni infection and following pre- or 
post-treatment with the commercially available pro-
biotic compound VSL#3. Upon comparable and stable 
pathogenic as well as probiotic bacterial colonization of 
the intestinal tract, VSL#3 could not sufficiently decrease 
intestinal C. jejuni loads in a biologically relevant man-
ner within 3  weeks following initial bacterial challenge. 
Lowering the bacterial loads in livestock animals includ-
ing poultry would be of great benefit in decreasing dis-
ease transmission rates to humans via the food chain, 
while immunomodulatory effects such as attenuation of 
intestinal inflammation would additionally result in less 
severe disease progression in the host. Our data are in 
Fig. 7 Splenic secretion of pro- and anti-inflammatory cytokines in C. jejuni strain 81-176 and/or VSL#3 associated secondary abiotic mice. Second-
ary abiotic mice were perorally associated either with the probiotic compound VSL#3 (+VSL; white symbols) or with C. jejuni strain 81-176 (+Cj; 
black symbols) on day 0. In bacterial competition experiments VSL#3 associated mice were challenged with C. jejuni strain 81–176 5 days thereafter 
(+VSL + Cj) or, the other way around (+Cj + VSL), C. jejuni infected mice additionally associated with the probiotic compound. a TNF, b MCP-1, c 
IL-6 and d IL-10 concentrations were determined in ex vivo biopsies derived from spleen at day 21 upon initial bacterial association. Naive mice 
served as uninfected controls (black diamonds). Medians (black bars), numbers of analyzed animals (in parentheses) and levels of significance 
(p-values) determined by Mann–Whitney U test are given. Significant differences as compared to naive controls are indicated by asterisks (*p < 0.05; 
**p < 0.01; ***p < 0.001). Data were pooled from three independent experiments
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contrast to a previous study applying isolator-raised ger-
mfree BALB/c mice that had been re-associated with a 
complex human microbiota and treated with a probiotic 
mix of five different Lactobacillus and three Bifidobac-
terium strains [26]. Following peroral infection with C. 
jejuni the authors observed a complete eradication of C. 
jejuni from the small and large intestines of with probi-
otics pre-challenged “humanized” mice [26]. One needs 
to take into consideration, that the observed differences 
in pathogen-eradicative properties might be due to dif-
ferences in the used probiotic mixtures and could also 
be explained by different immunological features of the 
applied animal models. Due to the lacking contact to any 
bacterial ligands and subsequent absence of immunologi-
cal differentiation and stimulation, germfree mice exhibit 
only poorly-developed intestinal lymphatic tissues [34, 
35]. It is thus highly reasonable that the immunological 
repertoire in formerly isolator raised germfree mice sub-
stantially differs from the secondary abiotic mice applied 
here that had been born, raised and housed under con-
ventional conditions. In addition, reconstitution of sec-
ondary abiotic mice with eight different probiotic strains 
(abundant in the VSL#3 compound) might not be suffi-
cient to reconstitute the complex physiological prerequi-
sites for effective competition with C. jejuni for nutrients 
and niches. Instead, a well-orchestrated interplay of 
mucosal immunity and the intestinal intraluminal milieu 
determined by the concert of the complex microbiota 
plus beneficial probiotic strains might be required to suc-
cessfully combat and/or prevent from enteropathogenic 
infection.
Whereas neither antibiotic treatment nor bacterial re-
association compromised mice clinically, we detected 
more pronounced apoptotic responses in colonic epi-
thelia following C. jejuni infection as reported by us 
previously [12, 14, 30, 36–38]. Remarkably, C. jejuni 
induced apoptosis could be alleviated by both thera-
peutic and prophylactic VSL#3 application. This is well 
in line with a former study demonstrating the capacity 
of VSL#3 to attenuate epithelial apoptosis in a murine 
dextran sodium sulphate (DSS) induced colitis model 
[39]. Notably, less apoptosis was associated with more 
than three times increased numbers of colonic epithelial 
Ki67+ cells as compared to naive counterparts indicative 
for up-regulated regenerative properties upon therapeu-
tic as well as prophylactic VSL#3 treatment. Given that 
enhanced cell proliferative activity is essential in tissue 
repair and cell regeneration, and thus prevents from loss 
of epithelial integrity [40], this VSL#3 induced measure 
might counteract and prevent from pathogen-induced 
apoptosis. This mechanism has already been proposed 
for other probiotic species including E. coli Nissle 1917 
[27]. The anti-apoptotic properties exerted by VSL#3 
were further paralleled by a dampened C. jejuni induced 
recruitment of pro-inflammatory innate immune cell 
subsets including macrophages and monocytes as well 
as adaptive immune cell populations such as T lympho-
cytes, Treg and B lymphocytes into the large intestinal 
mucosa and lamina propria. A VSL#3 mediated attenu-
ated influx of pro-inflammatory immune cells into the 
colonic mucosa has already been shown in murine trini-
trobenzene sulfonic acid (TNBS) induced colitis [41]. 
Intestinal and extra-intestinal cytokine analyses in our 
study further revealed that both therapeutic and prophy-
lactic application of the probiotic compound resulted in 
increased colonic secretion of the anti-inflammatory key 
cytokine IL-10, whereas pro-inflammatory IL-6 concen-
trations were decreased in large intestines as compared 
to untreated C. jejuni infected mice. In addition, VSL#3 
prophylaxis resulted in decreased secretion of colonic 
MCP-1 upon C. jejuni infection. Most strikingly, anti-
inflammatory properties of VSL#3 were not restricted to 
the intestinal tract, but could also be observed systemi-
cally, given that prophylactic VSL#3 treatment attenu-
ated C. jejuni induced TNF and IL-12p70 secretion in 
the spleen. At the first glance it appeared somewhat 
confusing in this context that both mono- as well as pro-
phylactic probiotic bacterial co-colonization resulted in 
elevated levels of the pro-inflammatory cytokine TNF in 
colon and MLN. This result was, however, further sup-
ported by a former study demonstrating that VSL#3 can 
in fact stimulate the intestinal epithelium to produce TNF 
in response, which interestingly resulted in improved 
epithelial barrier function and prevention of intestinal 
disease such as experimental ileitis [42]. Furthermore, 
observations that TNF deficient mice were more suscep-
tible to acute DSS colitis have led to the concept that TNF 
might have protective functions in normal gut homeosta-
sis and intestinal epithelial integrity [43]. Prophylactic 
VSL#3 challenge dampened C. jejuni induced systemic 
TNF responses, however. While it may be physiologically 
important for the host to maintain a certain well-bal-
anced level of local inflammation as a proper response to 
enteropathogens, avoidance of extra-intestinal and sys-
temic inflammatory sequelae were pivotal for host health 
integrity. This further supports the dichotomic properties 
of cytokines depending on the respective (patho-)physio-
logical context and cytokine milieu determining whether 
the same cytokine acts rather pro- or anti-inflammatory 
[44, 45]. Our findings here further reinforce former data 
providing evidence for anti-inflammatory properties 
of VSL#3. For instance, VSL#3 has been shown to sup-
press MCP-1 production from human dendritic cells 
in vitro [46] and to down-regulate colonic MCP-1 mRNA 
expression also in vivo [47]. Moreover VSL#3 application 
could ameliorate recurrent Th1-mediated TNBS colitis 
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in mice by inducing IL-10 and IL-10-dependent regula-
tory T cells expressing TGF-β [48]. The observed immu-
nomodulatory effects of the probiotic compound might, 
at least in part, be attributed to the impact of probiotics 
on Toll-like receptor (TLR) expression [49]. We have pre-
viously reported that C. jejuni induced immunopathology 
depends on TLR-4- and TLR-9 signaling [12], whereas in 
a very recent study VSL#3 was shown to down-regulate 
TLR-2, TLR-3, TLR-4, and TLR-9 expression in  vitro 
[50]. Whether the observed beneficial effects can be 
attributed to single bacterial species out of the eight pro-
biotic strains within the compound VSL#3 or the mutu-
alistic/synergistic interaction of distinct strains warrants 
further investigations.
Conclusion
Our data presented here provide evidence that though not 
sufficiently enforcing pathogenic clearance, therapeutic as 
well as prophylactic VSL#3 application can induce anti-
inflammatory responses and limit not only intestinal, but 
also systemic pro-inflammatory sequelae of vertebrate C. 
jejuni infection. The probiotic compound VSL#3 might 
therefore further open up promising tools for prophylaxis 
and/or treatment of C. jejuni induced sequelae.
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